BRCA1 and neoplasm: Although the BRCA-like classifier was trained to be an independent test for HRD status, the likely clinical use will be to identify non–BRCA1/2-mutated HRD tumors, either with parallel tumor/germline DNA for BRCA1/2 mutation status for a comprehensive view or a stepwise testing algorithm if no BRCA1/2 mutation is identified in resource-limited situations.